Pramipexole reverses Parkinson's disease‐related motivational deficits in rats
- 11 February 2014
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 29 (7) , 912-920
Abstract
Recent evidence suggests that Parkinson's disease affects not only movement, but also cognitive and psychiatric functions. Among these nonmotor complications, apathy, which is defined as a lack of motivation and operationalized as a quantitative reduction in goal‐directed behavior, may even precede motor impairments, disappearing with the introduction of dopaminergic (DA) therapies and possibly reappearing with its discontinuation, suggesting a causal role of DA. We recently developed a lesion‐based model, with stereotaxic infusion of 6‐hydroxydopamine (6‐OHDA) into precise areas of the rat SNc or ventral tegmental area and showed, in several operant tasks, that a partial denervation of the nigrostriatal, but not of the mesocorticolimbic, DA system induced profound motivational deficits during instrumental action. We investigated the time course of the effects of nigrostriatal DA denervation on motivation in rats, by assessing the negative effect of SNc bilateral 6‐OHDA infusion on preacquired operant behavior, and determining whether the induced deficits were sensitive to the introduction and withdrawal of a clinically relevant PD treatment, the DA D2/D3 receptor agonist, pramipexole (PRA). Partial nigrostriatal DA denervation was accompanied by a significant reduction in operant behavior. This deficit, indicative of a decrease in motivation, was fully reversed by PRA and reappeared after treatment withdrawal. This longitudinal preclinical study provides evidence for the implication of the DA nigrostriatal system in PD‐associated apathy. Moreover, by showing a good isomorphy and predictive value, our model highlights the relevance of D2/D3 receptors as potential targets for alleviating apathy in PD. © 2014 International Parkinson and Movement Disorder SocietyKeywords
This publication has 55 references indexed in Scilit:
- Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behavioursBrain, 2012
- Dysthymia and Apathy: Diagnosis and TreatmentDepression Research and Treatment, 2011
- Goal-directed and habitual control in the basal ganglia: implications for Parkinson's diseaseNature Reviews Neuroscience, 2010
- Neuropsychiatric effects of subthalamic neurostimulation in Parkinson diseaseNature Reviews Neurology, 2010
- The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2009
- The effect of pramipexole on mood and motivational symptoms in parkinson's disease: A meta-analysis of placebo-controlled studiesClinical Therapeutics, 2009
- GDNF is a fast-acting potent inhibitor of alcohol consumption and relapseProceedings of the National Academy of Sciences, 2008
- Disconnecting force from money: effects of basal ganglia damage on incentive motivationBrain, 2008
- Medication-related impulse control and repetitive behaviors in Parkinson??s diseaseCurrent Opinion in Neurology, 2007
- Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's diseaseNeurobiology of Disease, 2005